Trial site
Lexington Medical Center
West Columbia, South Carolina 29169, United StatesNot linked to an institution yet
- 18running trials
- 8closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 23 trials
- Phase 2/31 trial
- Status
- Active, not recruiting12 trials
- Completed6 trials
- Recruiting6 trials
- Terminated2 trials
- Suspended1 trial
- Lead sponsor
- Alliance for Clinical Trials in Oncology4 trials
- ECOG-ACRIN Cancer Research Group4 trials
- Inari Medical3 trials
- National Cancer Institute (NCI)3 trials
- Boston Scientific Corporation2 trials
- and 9 more
Running trials
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Scott Graupner (principal investigator)
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Scott Graupner (principal investigator)
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· Phase 3· SWOG Cancer Research Network· Source
Contact: Steven A. Madden (principal investigator)
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· Phase 3· NRG Oncology· Source
Contact: Steven A. Madden (principal investigator)
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Steven A. Madden (principal investigator)
Active, not recruiting
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
CHAMPION-AF Clinical Trial
NCT04394546· Boston Scientific Corporation· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667· Boston Scientific Corporation· Source
Active, not recruiting
AMPLATZER PFO Occluder Post Approval Study
NCT03309332· Abbott Medical Devices· Source
Active, not recruiting
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685· Phase 3· Alliance Foundation Trials, LLC.· Source
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Blue Light Cystoscopy With Cysview® Registry
NCT02660645· Photocure· Source
Contact: Nicol Brandon
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error